A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Amgen Inc (NASDAQ: AMGN) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on December 23, 2016 and NASDAQ: AMGN investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 12/16/2016 -- A deadline is coming up on December 23, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Amgen Inc (NASDAQ: AMGN) between April 22, 2004 and May 10, 2007.
Investors who purchased a significant amount of shares of Amgen Inc (NASDAQ: AMGN) between April 22, 2004 and May 10, 2007, have certain options and should contact the Shareholders Foundation by email at email@example.com or call +1(858) 779 - 1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Amgen Inc (NASDAQ: AMGN) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/amgen-inc-nasdaq-amgn-investor-securities-class-action-lawsuit-04172007
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is December 23, 2016. The class action administrator for this case is Epiq.
The lawsuit was originally filed in the U.S. District Court for the Central District of California on behalf of investors who purchased Amgen Inc (NASDAQ: AMGN) common shares between May 4, 2005 through May 10, 2007.
April 17, 2007 - An investor in shares of Amgen Inc (NASDAQ: AMGN) filed a lawsuit in the U.S. District Court for the Central District of California against Amgen Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between May 4, 2005 March 9, 2007.
The complaint alleges that between May 4, 2005 March 9, 2007, defendants marketed Aranesp and Epogen to doctors for off-label uses. As a result, Amgen Inc sold several hundred million dollars worth of drugs each year for these off-label uses. In October 2006, a group of researchers halted a clinical study of head and neck cancer patients treated with Aranesp because more deaths occurred in patients taking Aranesp than in those taking a placebo. Amgen Inc did not disclose these results to investors. On February 16, 2007, a publication called The Cancer Letter published an article about the results of the study and on March 9, 2007, the FDA mandated a "black box" warning regarding the off-label use of Aranesp and Epogen. These revelations caused Amgen Inc (NASDAQ: AMGN) stock price to decline.
Those who purchased shares of Amgen Inc (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego